REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

NCT04162470 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
24
Enrollment
INDUSTRY
Sponsor class

Stopped Business Decision

Conditions

Interventions

Sponsor

Regeneron Pharmaceuticals